Relationships between drug company representatives and medical students: Medical school policies and attitudes of student affairs deans and third-year medical students

Academic Psychiatry

Volumn 33, Issue 6, 2009, Pages 478-483

  Sierles, Frederick S ^a   Brodkey, Amy ^b   Cleary, Lynn ^c   McCurdy, Frederick A ^d   Mintz, Matthew ^e   Frank, Julia ^e   Lynn, Deborah Joanne ^f   Chao, Jason ^g   Morgenstern, Bruce ^h   Shore, William ⁱ   Woodard, John ^j  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c State University New York College of Environmental Science and Forestry   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Mayo Clinic College of Medicine   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADMINISTRATIVE PERSONNEL; ARTICLE; ATTITUDE; CONTROLLED STUDY; DRUG MANUFACTURE; DRUG MARKETING; GIFT GIVING; HEALTH SURVEY; HUMAN RELATION; MEDICAL SCHOOL; MEDICAL STUDENT; POLICY;

ATTITUDE OF HEALTH PERSONNEL; CLINICAL CLERKSHIP; CONFLICT OF INTEREST; DATA COLLECTION; DRUG INDUSTRY; ETHICS, MEDICAL; FACULTY, MEDICAL; GUIDELINE ADHERENCE; HUMANS; INTERPROFESSIONAL RELATIONS; ORGANIZATIONAL POLICY; PSYCHIATRY; SCHOOLS, MEDICAL; STUDENTS, MEDICAL; UNITED STATES;

EID: 72149085695     PISSN: 10429670     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ap.33.6.478     Document Type: Article

References (35)

1. Sierles FS, Brodkey AC, Cleary LM, et al: Medical students' exposure to and attitudes about drug company interactions. JAMA 2005; 294:1034-1042
2. Wazana A: Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000; 283:373-380
3. Brodkey AC: The role of industry in teaching psychopharmacology: a growing problem. Acad Psychiatry 2005; 29: 222-229
4. Sigworth SK, Cohen GM: Pharmaceutical branding of resident physicians. JAMA 2001; 286:1024-1025
5. Campbell EG, Gruen RL, Mountford J, et al: A national survey of physician-industry relationships. N Engl J Med 2007; 356:1742-1750
6. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research. JAMA 2003; 289:454-465
7. Lexchin J, Bero LA, Djulbegovic B, et al: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326:1167-1173
8. Heres S, Davis J, Maino K, et al: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163:185-194 (Pubitemid 44480836)
9. Montgomery JH, Byerly M, Carmody T, et al: An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials 2004; 25:598-612 (Pubitemid 39592864)
10. Baker CB, Johnsrud MT, Crismon ML, et al: Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003; 183:498-506
11. Safer DJ: Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002; 190:583-592
12. Melander H, Ahlqvist-Rastad J, Meijer G, et al: Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. Br Med J 2003; 326:1-5
13. Taylor MA, Fink M: Melancholia. New York, Cambridge University Press, 2006, pp 196-210
14. Avorn J, Chen M, Hartley R: Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982; 73:4-8 (Pubitemid 12048270)
15. Orlowski JP, Wateska L: The effects of pharmaceutical firm enticements on physician prescribing patterns: there's no such thing as a free lunch. Chest 1992; 102:270-273
16. Siegel D, Lopez J: Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? JAMA 1997; 278:1745-1748
17. Schwartz TL, Kuhles DL II, Wade M, et al: Newly-admitted psychiatric patient prescriptions and pharmaceutical sales visits. Ann Clin Psychiatry 2001; 15:159-162 (Pubitemid 34020151)
18. Schneeweis S, Glynn RJ, Avorn J, et al: A Medicare data base review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol 2005; 58:98-102 (Pubitemid 40093118)
19. Chew LD, O'Young TS, Hazlet TK, et al: A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Int Med 2000; 15:478-483
20. Mintzes B, Barer ML, Kravitz RL, et al: How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Can Med Assn J 2003; 169:405-412 (Pubitemid 37076252)
21. Chren MM, Landefeld S: Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994; 271:684-689
22. Studdert DM, Mello MM, Brennan TA: Financial conflicts of interest in physicians' relationships with the pharmaceutical industry-self-regulation in the shadow of federal prosecution. N Eng J Med 2004; 351:1891-1900
23. American Medical Student Association: Principles regarding pharmaceuticals and medical devices. Available at www. amsa.org/about/ppp/pharm. cfm
24. Brennan TA, Rothman DJ, Blank L, et al: Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006; 295:429-433 (Pubitemid 43144979)
25. Geppert CMA: Medical education and the pharmaceutical industry: a review of ethical guidelines and their implications for psychiatric training. Acad Psychiatry 2007; 31:32-39
26. Association of American Medical Colleges: New AAMC task force to examine industry influence on medical education, 2006
27. Association of American Medical Colleges: Report of the AAMC Task Force on Industry Funding of Medical Education to the AAMC Executive Council. Washington, DC, 2008
28. Sears J: Implementing the Recommendations of the AAMC Task Force on Industry Funding of Medical Education: A Selected Policy Language Compendium. Washington, DC, Association of American Medical Colleges, 2008
29. Lo B, Field MJ: Conflicts of Interest in Research, Education and Practice. Institute of Medicine of the National Academies, National Academies Press, Washington, DC, 2009
30. Accreditation Council of Graduate Medical Education: Principles to guide the relationships between graduate medical education and industry, 2002. Available at http://www. acgme.org/acWebsite/positionPapers/pp-GMEGuide.pdf
31. Psychiatry Residency Review Committee: Program Information Form, 2009. Available at http://www.acgme.org/ acWebsite/downloads/RRC-PIF/PIFS-JAN312008/ 400- PsychiatryContinued-082007-u01312008.doc
32. American Medical Student Association: AMSA PharmFree Scorecard, 2007. Available at www.amsa.org/prof/pharmfree. cfm
33. American Medical Student Association: AMSA PharmFree Scorecard, 2009. Conflict of interest policies at academic medical centers. Available at www2.amsascorecard.org
34. Sierles FS: How to do research with self-administered surveys. Acad Psychiatry 2003; 27:104-113
35. Varley CK, Jibson MD, McCarthy M, et al: A survey of the interactions between psychiatry residency programs and the pharmaceutical industry. Acad Psychiatry 2005; 29:40-46 (Pubitemid 40300208)